Technology Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology AIT News Desk Jan 9, 2023 Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology.…
Life Sciences Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate AIT News Desk Jun 22, 2022 Kiromic BioPharma, Inc. a clinical-stage biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) and data mining platform…
Life Sciences Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored… AIT News Desk Jun 8, 2022 In Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel, Isocel,…
Life Sciences Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007… AIT News Desk Mar 21, 2022 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2…
Life Sciences Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies AIT News Desk Mar 21, 2022 Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the…
Healthcare Management Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating… AIT News Desk Feb 25, 2022 New data demonstrate eradication of solid tumors in preclinical study Aulos Bioscience, an immuno-oncology company working to revolutionize…
Healthcare Management Exact Sciences And OncXerna Announce Licensing Agreement To Help Predict Immunotherapy Response For… AIT News Desk Jan 10, 2022 Agreement grants a license to Exact Sciences for OncXerna's Xerna™ TME Panel adding to its comprehensive tumor profiling solution, GEM ExTra®…
Healthcare Management Immunomic Therapeutics Announces Collaboration With iOncologi AIT News Desk Nov 24, 2021 - Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors Immunomic Therapeutics, Inc., (“ITI”) a privately held…